Skip to main content
Clinical Trials/NCT02375269
NCT02375269
Unknown
Not Applicable

A Randomized, Double- Blind Multicentric Study of the Effect of Remote Ischemic Preconditioning on Postoperative Complications in Patients Undergoing Major Minimal and Open Visceral Surgery

University of Zurich1 site in 1 country526 target enrollmentMarch 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postoperative Complication
Sponsor
University of Zurich
Enrollment
526
Locations
1
Primary Endpoint
Postoperative Complications
Last Updated
11 years ago

Overview

Brief Summary

Remote Ischemic Preconditioning (RIPC) is mediated by intermittent brief episodes (5-10 minutes) of short ischemia in a limb (i.e. arm), followed by reperfusion. For this purpose in 3-4 cycles, a tourniquet is insufflated to suprasystolic pressure levels for 5 minutes and deflated for 5 minutes afterwards. The ischemic episodes are known to stimulate platelets and factors platelet dependent factors such as Serotonin and VEGF. These humoral factors have a systemic effect and have the potential to protect target organs (i.e. heart, kidney, liver) remote to the ischemic limb.

The purpose of this randomized controlled study is to investigate the influence and impact of RIPC on postoperative complications in patients undergoing visceral surgery

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
March 2018
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \> 18 years
  • Undergoing major visceral surgery

Exclusion Criteria

  • \< 18 years
  • Pregnancy
  • Signs of Infection/Inflammation on upper limb
  • Medical history of axillary lymph node dissection
  • Signs of malperfusion of upper limb (i.e. Allen Test)
  • Missing informed consent

Outcomes

Primary Outcomes

Postoperative Complications

Time Frame: 30 days

Complications will be assessed by Comprehensive Complication Index and Dindo Clavien Score

Secondary Outcomes

  • Hospital stay(30 days)
  • ICU stay(30 days)
  • Infection composite parameters(30 days)

Study Sites (1)

Loading locations...

Similar Trials